Sabby Management, LLC Vincerx Pharma, Inc. Transaction History

Sabby Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.66 - $1.38 $30,193 - $63,130	-45,747 Reduced 44.37%	57,353 $57,000
Q2 2023 Aug 14, 2023	SELL	$0.88 - $1.9 $220,264 - $475,570	-250,300 Reduced 70.83%	103,100 $134,000
Q1 2023 May 15, 2023	SELL	$0.9 - $1.51 $131,940 - $221,366	-146,600 Reduced 29.32%	353,400 $367,000
Q4 2022 Feb 14, 2023	SELL	$0.64 - $1.32 $3,557 - $7,337	-5,559 Reduced 1.1%	500,000 $510,000
Q3 2022 Nov 14, 2022	BUY	$0.0 - $1.72 $0 - $8,600	5,000 Added 1.0%	505,559 $698,000
Q2 2022 Aug 15, 2022	BUY	$0.0 - $0.0 $0 - $0	173,323 Added 52.97%	500,559 $661,000
Q1 2022 May 16, 2022	BUY	$0.0 - $0.0 $0 - $0	68,347 Added 26.4%	327,236 $1.31 Million
Q4 2021 Feb 14, 2022	BUY	$0.0 - $0.0 $0 - $0	58,889 Added 29.44%	258,889 $2.64 Million
Q3 2021 Nov 15, 2021	SELL	$0.0 - $0.0 $0 - $0	-71,063 Reduced 26.22%	200,000 $3.23 Million
Q2 2021 Aug 16, 2021	BUY	$0.0 - $27.0 $0 - $5.08 Million	188,115 Added 226.79%	271,063 $3.52 Million
Q1 2021 May 17, 2021	BUY	$22.6 - $31.0 $1.87 Million - $2.57 Million	82,948 New	82,948 $1.6 Million

11M

Ticker VINC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,189,800
Market Cap $4.03M
Description
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sabby Management, LLC with notifications on news.